Search Results

Paul Beavis

I am an Assoc. Prof. and Group Leader at the Peter MacCallum Cancer Centre (Peter Mac; Melbourne, Australia).

Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma

Chimeric antigen receptor (CAR) T cell therapy is a form of therapy where a patient’s own immune cells are genetically engineered to recognize and ki…

Exploiting escape from Y-inactivation as a synthetic dependency in MYC-driven lymphoma

Chimeric antigen receptor (CAR) T cell therapy is a form of therapy where a patient’s own immune cells are genetically engineered to recognize and ki…

Paul Beavis

I am an Assoc. Prof. and Group Leader at the Peter MacCallum Cancer Centre (Peter Mac; Melbourne, Australia).

Development of a clinical program for myeloid cancer prevention

Tmdshe majority of myeloid cancers remain incurable. We previously showed that individuals at risk can be identified years in advance, indicating that…

A phase 1 expansion study of IO-202, an antibody targeting LILRB4, in combination with azacitidine in patients with monocytic differentiation AML and CMML

In March , LLS made an equity investment in Therapeutics to support the "Phase Clinical Development of , An Antibody Targeting LILRB4, for the Treat…

Bailee Kain

Dr. Bailee Kain is from Geneseo, IL and received her B.S. in Biochemistry from University of Missouri in . She completed her doctoral thesis work at B…

Nataly Cruz-Rodriguez

I have a deep passion for understanding how hematological malignancies develop from hematopoietic stem cells.

Bingyi Chen

I am a Research Scholar in the laboratory of Dr. Omar at Memorial Sloan Kettering Cancer Center.

James Rubenstein

Dr. Rubenstein is an internationally recognized authority on the research and treatment of patients with primary and secondary CNS lymphoma.

James Rubenstein

Peter Croucher

Peter trained at the University of Wales College of Medicine and Cambridge and Oxford Universities in the UK. In he joined Sheffield University and b…

A phase 2 expansion study of ICT01, an anti-BTN3A monoclonal antibody, in combination with azacitidine and venetoclax in patients with AML

In June , LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications."Im…

Dissecting the mitochondrial alterations by aberrant NPM1 to the pathogenesis of myelodysplastic syndrome

Survival rates for those afflicted with MDS have not improved despite extensive effort to identify the key genetic events in its pathogenesis. This pr…

New Targeted Therapies for Pediatric Acute Myeloid Leukemia

Our research focuses on the preclinical evaluation of new targeted therapies for subtypes of childhood AML. We are deploying screening approaches to …

Eric Vick

Dr. Eric Vick is a and instructor at the University of Cincinnati focused on novel translational therapies for myeloid neoplasia. He is originally fr…

Genomics of Diffuse Large B Cell Lymphoma: pervasive role of super-enhancer hypermutation in dysregulating oncogene expression

We recently identified a pervasive, pathogenically relevant mutational mechanism that targets (SE) in DLBCL, leading to target gene deregulation. Her…